Blackrock, INC Schedule 13G passive stakes
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, reporting a 6.3% beneficial ownership stake in Willdan Group, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 2 to Schedule 13G, disclosing a 6.7% passive beneficial ownership stake in Adaptive Biotechnologies Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting beneficial ownership of 8.3% of Agilent Technologies Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% passive ownership stake in Akebia Therapeutics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 6.7% Stake in American Public Education Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in American Public Education Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in AngioDynamics Inc.
BlackRock, Inc. has filed an Amendment No. 8 to Schedule 13G, disclosing a 7.2% passive beneficial ownership stake in AngioDynamics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 8.7% Passive Stake in ANSYS Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.7% of ANSYS Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 6 to its Schedule 13G, reporting a 12.4% beneficial ownership stake in Astrana Health, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, disclosing a 5.8% beneficial ownership stake in AutoNation, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 5.7% Stake in Beyond Meat, Files Updated Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 5.7% of Beyond Meat, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership of 8.5% of Biogen Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing a 7.5% beneficial ownership stake in Builders FirstSource, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.9% Stake in Claros Mortgage Trust Inc.
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.9% in Claros Mortgage Trust Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock, Inc. Discloses 8.5% Passive Stake in Coherent Corp.
BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.5% beneficial ownership stake in Coherent Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 6.6% beneficial ownership stake in Coherus BioSciences Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Cooper Standard Holdings Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, confirming its beneficial ownership of 8.9% of Crown Castle Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its significant 9.0% beneficial ownership stake in D.R. Horton, Inc. common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 9.1% Passive Stake in Dynex Capital Inc.
BlackRock, Inc. has filed an updated Schedule 13G, revealing a 9.1% beneficial ownership stake in Dynex Capital Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 5.8% Passive Stake in Dyne Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.8% passive beneficial ownership stake in Dyne Therapeutics, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a 7.9% beneficial ownership stake in Editas Medicine, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Passive Stake in Enanta Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Enanta Pharmaceuticals Inc. as of March 31, 2025, indicating a passive investment.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 9.2% beneficial ownership stake in Envista Holdings Corp., held for passive investment purposes.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 16.9% of the common stock of Essential Properties Realty Trust, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.0% Stake in EVgo Inc. Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in EVgo Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 6.8% of FrontView REIT, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 7.5% Stake in Guardant Health, Files Updated Beneficial Ownership Report
BlackRock, Inc. has filed an updated Schedule 13G, reaffirming its substantial passive ownership of 7.5% of Guardant Health, Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in McKesson Corporation as of March 31, 2025, held for ordinary course of business.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 7.8% beneficial ownership stake in AMC Networks Inc.'s Class A Stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its significant passive stake in AECOM, holding 9.8% of the common stock as of March 31, 2025.